<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34895935</PMID><DateCompleted><Year>2022</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>3</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>24</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Prior COVID-19 infection is associated with increased Adverse Events (AEs) after the first, but not the second, dose of the BNT162b2/Pfizer vaccine.</ArticleTitle><Pagination><StartPage>418</StartPage><EndPage>423</EndPage><MedlinePgn>418-423</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2021.11.090</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(21)01577-2</ELocationID><Abstract><AbstractText>The BNT162b2/Pfizer SARS-CoV-2 vaccine has been widely used in the UK, particularly amongst healthcare workers (HCWs). To establish whether previous COVID-19 influenced vaccine-associated Adverse Events (AEs), we conducted a survey-based study of HCWs in Northeast England. Out of 1238 HCWs, 32% self-reported prior positive PCR and/or antibody test for SARS-CoV-2. Post-dose AEs were worse in those with prior COVID-19 after the first, but not the second dose of vaccine. Second dose AEs were greater in frequency/severity, regardless of COVID-19 history, and they were more systemic in nature. Women and younger HCW were more likely to report AEs after both doses, while dosing interval had no effect on AEs. Ongoing Symptomatic COVID-19 was associated with greater frequency/severity of AEs after dose 2, but not dose one. Overall, AEs were self-limiting and short-lived (i.e.,&lt;48&#xa0;h) in nature. These findings have implications for vaccine hesitancy and informing guidelines for recommended dosing protocols.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Raw</LastName><ForeName>Rachael K</ForeName><Initials>RK</Initials><AffiliationInfo><Affiliation>School of Medicine and Health, Newcastle University, Newcastle upon Tyne, UK. Electronic address: Rachael.raw3@nhs.net.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rees</LastName><ForeName>Jon</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The School of Psychology, University of Sunderland, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelly</LastName><ForeName>Clive A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>The Department of Rheumatology, James Cook University Hospital, Middlesbrough, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wroe</LastName><ForeName>Caroline</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>The Department of Nephrology, James Cook University Hospital, Middlesbrough, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chadwick</LastName><ForeName>David R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Centre for Clinical Infection, James Cook University Hospital, Middlesbrough, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>N38TVC63NU</RegistryNumber><NameOfSubstance UI="D000090982">BNT162 Vaccine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000090982" MajorTopicYN="Y">BNT162 Vaccine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000088823" MajorTopicYN="N">Vaccination Hesitancy</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">COVID-19 Vaccination</Keyword><Keyword MajorTopicYN="N">Long-COVID</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vaccine Hesitancy</Keyword><Keyword MajorTopicYN="N">Vaccine-Associated Adverse Events</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>11</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>13</Day><Hour>12</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>12</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34895935</ArticleId><ArticleId IdType="pmc">PMC8642150</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2021.11.090</ArticleId><ArticleId IdType="pii">S0264-410X(21)01577-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Polack F.P., Thomas S.J., Kitchin N., Absalon J., Gurtman A., Lockhart S., et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603&#x2013;2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Baden L.R., El Sahly H.M., Essink B., Kotloff K., Frey S., Novak R., et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403&#x2013;416. doi: 10.1056/NEJMoa2035389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2035389</ArticleId><ArticleId IdType="pmc">PMC7787219</ArticleId><ArticleId IdType="pubmed">33378609</ArticleId></ArticleIdList></Reference><Reference><Citation>Kadali R.A.K., Janagama R., Peruru S., Malayala S.V. Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. Int J Infect Dis. 2021;106:376&#x2013;381. doi: 10.1016/j.ijid.2021.04.047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.04.047</ArticleId><ArticleId IdType="pmc">PMC8049195</ArticleId><ArticleId IdType="pubmed">33866000</ArticleId></ArticleIdList></Reference><Reference><Citation>Krammer F., Srivastava K., Alshammary H., Amoako A.A., Awawda M.H., Beach K.F., et al. Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. N Engl J Med. 2021;384(14):1372&#x2013;1374. doi: 10.1056/NEJMc2101667.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2101667</ArticleId><ArticleId IdType="pmc">PMC8008743</ArticleId><ArticleId IdType="pubmed">33691060</ArticleId></ArticleIdList></Reference><Reference><Citation>Tr&#xe9;-Hardy M., Cupaiolo R., Papleux E., Wilmet A., Horeanga A., Antoine-Moussiaux T., et al. Reactogenicity, safety and antibody response, after one and two doses of mRNA-1273 in seronegative and seropositive healthcare workers. J Infect. 2021;83(2):237&#x2013;279. doi: 10.1016/j.jinf.2021.03.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.03.025</ArticleId><ArticleId IdType="pmc">PMC8012163</ArticleId><ArticleId IdType="pubmed">33811939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebinger J.E., Fert-Bober J., Printsev I., Wu M., Sun N., Prostko J.C., et al. Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2. Nat Med. 2021;27(6):981&#x2013;984. doi: 10.1038/s41591-021-01325-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01325-6</ArticleId><ArticleId IdType="pmc">PMC8205849</ArticleId><ArticleId IdType="pubmed">33795870</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathioudakis AG, Ghrew M, Ustianowski A et al. Self-reported real-world safety and reactogenicity of COVID-19 vaccines: An international vaccine-recipient survey. MedRxiv 2021; 2021.02.26.21252096. doi: https://doi.org/10.1101/2021.02.26.21252096.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8002738</ArticleId><ArticleId IdType="pubmed">33803014</ArticleId></ArticleIdList></Reference><Reference><Citation>Raw R.K., Kelly C.A., Rees J., Wroe C., Chadwick D.R. Previous COVID-19 infection, but not Long-COVID, is associated with increased adverse events following BNT162b2/Pfizer vaccination. J Infect. 2021;S0163&#x2013;4453(21):00277&#x2013;282. doi: 10.1016/j.jinf.2021.05.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2021.05.035</ArticleId><ArticleId IdType="pmc">PMC8164507</ArticleId><ArticleId IdType="pubmed">34062184</ArticleId></ArticleIdList></Reference><Reference><Citation>Manisty C., Otter A.D., Treibel T.A., McKnight &#xc1;., Altmann D.M., Brooks T., et al. Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals. Lancet. 2021;397(10279):1057&#x2013;1058. doi: 10.1016/S0140-6736(21)00501-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00501-8</ArticleId><ArticleId IdType="pmc">PMC7972310</ArticleId><ArticleId IdType="pubmed">33640038</ArticleId></ArticleIdList></Reference><Reference><Citation>Saadat S., Rikhtegaran Tehrani Z., Logue J., Newman M., Frieman M.B., Harris A.D., et al. Binding and Neutralization Antibody Titers After a Single Vaccine Dose in Health Care Workers Previously Infected With SARS-CoV-2. JAMA. 2021;325(14):1467. doi: 10.1001/jama.2021.3341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.3341</ArticleId><ArticleId IdType="pmc">PMC7922233</ArticleId><ArticleId IdType="pubmed">33646292</ArticleId></ArticleIdList></Reference><Reference><Citation>Prendecki M., Clarke C., Brown J., Cox A., Gleeson S., Guckian M., et al. Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine. Lancet. 2021;397(10280):1178&#x2013;1181. doi: 10.1016/S0140-6736(21)00502-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00502-X</ArticleId><ArticleId IdType="pmc">PMC7993933</ArticleId><ArticleId IdType="pubmed">33640037</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec; A., Bernabei R., Landi F. Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 2020;324(6):603&#x2013;605. doi: 10.1001/jama.2020.12603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.12603</ArticleId><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunders M.J., Altfeld M. Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions. Immunity. 2020;53(3):487&#x2013;495. doi: 10.1016/j.immuni.2020.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2020.08.003</ArticleId><ArticleId IdType="pmc">PMC7430299</ArticleId><ArticleId IdType="pubmed">32853545</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolgin E. Is one vaccine dose enough if you've had COVID? What the science says. Nature. 2021;595(7866):161&#x2013;162. doi: 10.1038/d41586-021-01609-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/d41586-021-01609-4</ArticleId><ArticleId IdType="pubmed">34176923</ArticleId></ArticleIdList></Reference><Reference><Citation>Food and Drug Administration. Guidance for Industry Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials. 2021. https://www.fda.gov/media/73679/download (accessed July 25, 2021).</Citation></Reference><Reference><Citation>National Institute of Clinical Excellence (NICE), the Scottish Intercollegiate Guidelines Network (SIGN), and the Royal College of General Practitioners (RCGP). NICE &#x2018;long COVID&#x2019; guideline. 2021. https://www.guidelines.co.uk/infection/nice-long-covid-guideline/455728.article (accessed November 11, 2021).</Citation></Reference><Reference><Citation>Freeman D, Loe BS, Chadwick A et al. COVID-19 vaccine hesitancy in the UK: the Oxford coronavirus explanations, attitudes, and narratives survey (Oceans) II. Psychol Med. 2020:1-15. doi: 10.1017/S0033291720005188.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7804077</ArticleId><ArticleId IdType="pubmed">33305716</ArticleId></ArticleIdList></Reference><Reference><Citation>Machingaidze S., Wiysonge C.S. Understanding COVID-19 vaccine hesitancy. Nat Med. 2021;27(8):1338&#x2013;1339. doi: 10.1038/s41591-021-01459-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01459-7</ArticleId><ArticleId IdType="pubmed">34272500</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson E., Reeve K.S., Niedzwiedz C.L., Moore J., Blake M., Green M., et al. Predictors of COVID-19 vaccine hesitancy in the UK household longitudinal study. Brain Behav Immun. 2021;94:41&#x2013;50. doi: 10.1016/j.bbi.2021.03.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.03.008</ArticleId><ArticleId IdType="pmc">PMC7946541</ArticleId><ArticleId IdType="pubmed">33713824</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>